Small Cell Lung Cancer

Timothy Murphy, MD, FACP, practice president of Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the effect of the COVID-19 pandemic on screening for lung cancer.

This new study has found different labs followed similar practices, but the way they scored patients varied significantly.

Timothy Murphy, MD, FACP, current practice president at Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the current state of lung cancer screenings.

This experimental research suggests the expression levels of certain genes might help explain why people with lung cancer often have more severe cases of COVID-19.

Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.

The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.

The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke about the use of precision medicine approaches, such as the nicotine metabolite ratio (NMR), to improve outcomes for patients with lung cancer.

Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.

Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke on increased rates of smoking and lung cancer within a particular region of the United States called "Tobacco Nation."

The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.

Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.

A recent study stresses the importance of routine CT screening for improving lung cancer survival outcomes.

The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.

Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.

The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

A new report underscores how treatment decisions for non-small cell lung cancer (NSCLC) affect patients’ health care utilization and costs.

Immune checkpoint inhibitors, either alone or in combination with chemotherapy, were associated with better outcomes in non–oncogene-addicted non–small cell lung cancer (NSCLC).

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.

Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.

Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

Molecular differences may help explain geographic gaps in outcomes.

A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.

In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.

Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.